Active Ingredient History
Ramipril (sold under the brand name Altace ) is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitors. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril is indicated for the treatment of hypertension, to lower blood pressure; also used to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes; in addition, this drug is used to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Heart Failure (approved 1991)
Myocardial Infarction (approved 1991)
Acute Coronary Syndrome (Phase 4)
Albuminuria (Phase 4)
Alzheimer Disease (Phase 4)
Angina, Stable (Early Phase 1)
Angiotensin-Converting Enzyme Inhibitors (Phase 4)
Angiotensin Receptor Antagonists (Phase 4)
Antihypertensive Agents (Phase 4)
Aortic Valve Disease (Phase 4)
Arthritis, Rheumatoid (Phase 2/Phase 3)
Atherosclerosis (Phase 4)
Atrial Fibrillation (Phase 3)
Atrial Flutter (Phase 3)
Atrial Function, Left (Phase 4)
Blood Glucose (Phase 3)
Blood Pressure (Phase 4)
Breast Neoplasms (Phase 3)
Cardiomyopathy, Dilated (Phase 3)
Cardiopulmonary Bypass (Phase 4)
Cardiotoxicity (Phase 3)
Cardiovascular Diseases (Phase 4)
Chemoradiotherapy (Phase 2)
Child (Phase 3)
Cognitive Dysfunction (Phase 2)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
COVID-19 (Phase 3)
Creatinine (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 3)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 4)
Endothelial Cells (Phase 3)
Essential Hypertension (Phase 4)
Fibrinolysis (Phase 4)
Fractures, Bone (Phase 3)
Glioblastoma (Phase 2)
Glomerulonephritis (Phase 3)
Glomerulonephritis, IGA (Phase 4)
Glucose Intolerance (Phase 3)
Glucose Metabolism Disorders (Phase 3)
Growth and Development (Phase 3)
Healthy Volunteers (Phase 4)
Heart Diseases (Phase 4)
Heart Failure (Phase 4)
Heart Failure, Diastolic (Phase 4)
Hemodialysis, Home (Phase 2)
Hypercholesterolemia (Phase 2)
Hypertension ()
Hypertrophy, Left Ventricular (Phase 3)
Hypotension (Phase 4)
Inflammation (Phase 4)
Insulin Resistance (Phase 4)
Intermittent Claudication (Phase 4)
Kidney Diseases (Phase 3)
Kidney Failure, Chronic (Phase 3)
Kidney Transplantation (Phase 4)
Liver Diseases (Phase 3)
Lupus Erythematosus, Systemic (Phase 2/Phase 3)
Metabolic Syndrome (Phase 4)
Microvascular Angina (Phase 4)
Mitral Valve (Phase 3)
Mitral Valve Stenosis (Phase 3)
Muscular Dystrophy, Duchenne (Phase 4)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 3)
Neoplasms (Phase 3)
Obesity (Phase 3)
Oxidative Stress (Phase 3)
Peptidyl-Dipeptidase A (Phase 4)
Peripheral Arterial Disease (Phase 4)
Proteinuria (Phase 4)
Radiotherapy (Phase 2)
Renal Dialysis (Phase 2/Phase 3)
Renal Insufficiency, Chronic (Phase 4)
Renin-Angiotensin System (Phase 4)
Rheumatic Heart Disease (Phase 3)
Sclerosis (Phase 3)
Stroke (Phase 4)
Therapeutic Equivalency (Phase 1)
Vascular Diseases (Phase 4)
Vasculitis (Phase 2)
Ventricular Dysfunction, Left (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
